Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.71 |
| ▸ | MAOA | P21397 | 3/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | COMT | P21964 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834698 | 1.00 | AKR1B1 (0.71) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL6692200 | 0.83 | PPARG (0.68) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL6692202 | 0.83 | PPARG (0.68) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL4834121 | 0.82 | AKR1B1 (0.61) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL4834130 | 0.82 | AKR1B1 (0.61) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL2172983 | 0.81 | AURKA (0.64) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL2172979 | 0.81 | AURKA (0.64) | AKR1B1MAOAMAOBLMNAMAPT | |
| SCHEMBL15816886 | 0.81 | PPARG (0.60) | AKR1B1MAOAMAOBPTPN1PPARG | |
| SCHEMBL15816888 | 0.81 | PPARG (0.60) | AKR1B1MAOAMAOBPTPN1PPARG | |
| SCHEMBL15816884 | 0.81 | PPARG (0.60) | AKR1B1MAOAMAOBPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | AKR1B1 393/4885MAOA 1368/4885MAOB 881/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | AKR1B1 393/4885MAOA 1368/4885MAOB 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.